FindTrial
Sign In

Application of recombinant human acidic fibroblast growth factor in microskin grafting of extremely severe burns

Application of recombinant human acidic fibroblast growth factor in microskin grafting of extremely severe burns

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073444
Enrollment
Unknown
Registered
2023-07-11
Start date
2023-07-11
Completion date
Unknown
Last updated
2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

critical burn

Interventions

Experimental group:Spray recombinant human acidic fibroblast growth factor 100u/cm2
Control group:null

Sponsors

Anshan Hospital of the First Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1, aged between 18 and 65 years old (18 years old = age =65 years old); 2. Thermal (flame, hydrothermal) burn patients; 3. Patients with critical burn and microskin grafting.

Exclusion criteria

Exclusion criteria: 1. Burn patients caused by non-thermal factors (electrical contact, chemistry, radiation, etc.); 2. Patients who have participated in other drug clinical trials or are participating in other clinical trials within 1 month before participating in this trial; 3. Patients with severe vascular disease, diabetes complications, cancer, pregnancy, drug allergy, important organ dysfunction,immunosuppression, etc.

Design outcomes

Primary

MeasureTime frame
Percentage of wound healing at the time of allogenic skin detachment;—

Secondary

MeasureTime frame
Postoperative microskin healing time;—

Countries

CHINA

Contacts

Public ContactHongjun Zhai

Anshan Hospital of the First Hospital of China Medical University

hongjunzhai@163.com+86 180 4120 1012

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026